TORC1 inhibition enhances immune function and reduces infections in the elderly
Open accessPublished version of a preprint
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
Treating elderly subjects with two low-dose mTOR inhibitors that selectively block TORC1 led to a decrease in infection rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the case of SASP inhibitors, continuous treatment is needed to maintain suppression of the SASP, although some agents, such as rapamycin, can have prolonged effects after a brief course of administration116,117.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be a result of inhibiting SASP-mediated spread of senescence, thereby allowing the innate and adaptive immune system to further reduce senescent cell burden, consistent with the Unitary Theory (Fig. 2).”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“another anti-inflammatory that has been shown to improve efficacy of the flu vaccine in older adults is RAD001 which is a mammalian target of rapamycin complex 1 (TORC1) specific inhibitor (148).”
From The impact of ageing on monocytes and macrophages (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients ameliorated their immune response, with improved hematopoietic stem cell function and a decreased proportion of PD-1+ lymphocytes (206).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [206]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two low-dose everolimus regimens improved immune function without causing serious side effects.”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [206]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 3×
“Many of the beneficial effects of mTOR inhibition on aging may be mediated by inhibition of TORC1 (6, 7).”
Backgroundvoom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
mTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · cited 2×
“Many of the beneficial effects of mTOR inhibition on aging may be mediated by inhibition of TORC1 (6, 7).”
BackgroundMaira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082 · cited 1×
“Rapalogs such as RAD001 are a class of allosteric mTOR inhibitors that are derivatives of rapamycin and consistently inhibit only S6 kinase (S6K) downstream of TORC1 (10).”
BackgroundSerra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
mTOR inhibition improves immune function in the elderly
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009892 · Cited by 786
Self-citationmTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680 · cited 2×
“One of the aging-related conditions that improves in old mice treated with mTOR inhibitors is immunosenescence (the decline in immune function that occurs during aging) (3).”
BackgroundTransient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
Bitto, A., Ito, T. K., Pineda, V. V., LeTexier, N. J., Huang, H. Z., Sutlief, E., Tung, H., Vizzini, N., Chen, B., Smith, K., et al. (2016) · eLife · doi:10.7554/elife.16351 · Cited by 474
Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling
York, A. G., Williams, K. J., Argus, J. P., Zhou, Q. D., Brar, G., Vergnes, L., Gray, E. E., Zhen, A., Wu, N. C., Yamada, D. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.045 · Cited by 461
Graat, J. M., Schouten, E. G., & Kok, F. J. (2002) · JAMA · doi:10.1001/jama.288.6.715 · Cited by 230
Baumann, P., Mandl–Weber, S., Oduncu, F. S., & Schmidmaier, R. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.11.007 · Cited by 121
Depletion of Rictor, an essential protein component of m TORC 2, decreases male lifespan
Lamming, D. W., Mihaylova, M. M., Katajisto, P., Baar, E. L., Yilmaz, O. H., Hutchins, A., Gultekin, Y., Gaither, R., & Sabatini, D. M. (2014) · Aging Cell · doi:10.1111/acel.12256 · Cited by 111
Relieving Autophagy and 4EBP1 from Rapamycin Resistance
Nyfeler, B., Bergman, P., Triantafellow, E., Wilson, C. J., Zhu, Y., Radetich, B., Finan, P. M., Klionsky, D. J., & Murphy, L. O. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05430-11 · Cited by 94 · cited 11×
“M. E. Feldman, B. Apsel, A. Uotila, R. Loewith, Z. A. Knight, D. Ruggero, K. M. Shokat, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.”
BackgroundInfluentialRegulation of mTOR Activity in Snell Dwarf and GH Receptor Gene-Disrupted Mice
Dominick, G., Berryman, D. E., List, E. O., Kopchick, J. J., Li, X., Miller, R. A., & Garcia, G. G. (2015) · Endocrinology · doi:10.1210/en.2014-1690 · Cited by 79 · cited 1×
“In addition, several long-lived animal models have increased rather than decreased TORC2 activity (9).”
BackgroundIob, A., Brianti, G., Zamparo, E., & Gallo, T. (2005) · Epidemiology and Infection · doi:10.1017/s0950268805003936 · Cited by 77 · cited 1×
“2-fold increase in the influenza GMT ratio induced by the MF-59 vaccine adjuvant was associated with a decrease in influenza illness (17).”
BackgroundSchuierer, S., & Roma, G. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw538 · Cited by 51
Self-citationRAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
Nyfeler, B., Chen, Y., Li, X., Pinzon-Ortiz, M. C., Wang, Z., Reddy, A., Pradhan, E., Das, R., Lehár, J., Schlegel, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048548 · Cited by 31 · cited 2×
“8 nM Cmax) and 10 mg of BEZ235 (about 14 nM Cmax) in the current trial have been shown to synergistically inhibit the phosphorylation of both S6K and 4EBP1 downstream of TORC1 ex vivo (15).”
BackgroundHarari, D., Orr, I., Rotkopf, R., Baranzini, S. E., & Schreiber, G. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv071 · Cited by 16
Cited by
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
From discoveries in ageing research to therapeutics for healthy ageing
Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019) · Nature · doi:10.1038/s41586-019-1365-2 · Cited by 1,389
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Metadata
- Authors
- Mannick, J. B., Morris, M., Hockey, H.-U. P., Roma, G., Beibel, M., Kulmatycki, K., Watkins, M., Shavlakadze, T., Zhou, W., Quinn, D., Glass, D. J., & Klickstein, L. B.
- Affiliations
- Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
- Biometrics Matters Limited, Hamilton 3216, New Zealand.
- Novartis (Switzerland) (CH)
- P3 Research, Newtown, Wellington 6242, New Zealand.
- Corresponding author
- Mannick, Joan B.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-11
- Volume
- 10
- Issue
- 449
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2844364183
- Cited by
- 496
- References
- 24
- Citations by year
- 2026: 51 · 2025: 63 · 2024: 58 · 2023: 55 · 2022: 63 · 2021: 70 · 2020: 69 · 2019: 51 · 2018: 15
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science Translational Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- TORC1 inhibition, mTOR signaling, aging, immune function, infections in the elderly, antiviral gene expression, immunosenescence
- MeSH terms
- Everolimus, Mechanistic Target of Rapamycin Complex 1, Aged, Antibodies, Viral, Communicable Diseases, Dose-Response Relationship, Drug, Humans, Imidazoles, Immunity, Influenza, Human, Quinolines, Vaccination, Up-Regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.